OM · XBRL financial data

Outset Medical financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (OM's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	30	31*	28	27	29	29*	30	31	29	29*	28	32
Cost of goods and services sold	23	23*	20	18	19	19*	19	20	18	17*	16	18
Gross profit	7	8*	8	10	10	11*	11	12	12	12*	12	13
Research and development	16	13*	13	10	8	8*	6	5	5	5*	6	5
General and administrative	12	10*	11	13	10	9*	8	9	8	12*	10	11
Total operating expenses	53	45*	45	41	34	33*	27	29	27	30*	29	29
Operating income (loss)	(45)	(37)*	(37)	(31)	(24)	(22)*	(16)	(17)	(16)	(18)*	(17)	(16)
Interest expense	3	3*	6	6	6	6*	4	3	3	3*	3	3
Income tax expense (benefit)	0	0*	0	0	0	(0)*	0	0	0	0*	0	0
Net income (loss)	(46)	(39)*	(40)	(34)	(28)	(26)*	(26)	(19)	(18)	(19)*	(19)	(18)
Earnings per share, basic USD per share	(0.93)	—	(0.78)	(0.66)	(0.55)	—	(3.66)	(1.04)	(1.00)	—	(1.03)	(0.97)
Earnings per share, diluted USD per share	(0.93)	—	(0.78)	(0.66)	(0.55)	—	(3.66)	(1.04)	(1.00)	—	(1.03)	(0.97)
Weighted average shares, basic millions of shares	0	0*	0	0	0	0*	0	0	0	0*	0	0
Weighted average shares, diluted millions of shares	0	0*	0	0	0	0*	0	0	0	0*	0	0

† Share count changed about 1/3 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (OM's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	36	69	32	38	33	124	76	40	36	35	31	35
Short-term investments	158	135	195	157	142	35	113	145	142	134	126	112
Marketable securities	93	65	158	130	3	3	11	67	—	—	—	—
Accounts receivable	35	33	36	34	34	36	37	35	33	28	25	29
Inventory	48	49	56	62	61	59	56	52	49	48	50	47
Prepaid and other current assets	6	6	6	5	4	5	5	4	4	6	5	4
Total current assets	284	291	325	295	275	258	287	276	265	251	237	228
Property and equipment, net	14	13	12	11	9	8	7	6	5	5	4	4
Right-of-use asset	6	5	5	5	4	4	4	3	3	5	4	5
Total assets	308	314	346	315	293	276	301	289	277	264	249	242
Accounts payable	3	6	7	5	4	4	1	1	2	1	1	4
Total current liabilities	53	55	51	43	42	45	34	37	37	38	38	44
Long-term debt	97	130	197	197	197	197	94	95	96	96	97	98
Lease liability, non-current	5	4	4	4	3	3	2	2	1	3	3	3
Total liabilities	155	191	253	246	245	249	131	134	135	138	138	146
Accumulated deficit	(923)	(962)	(1,002)	(1,036)	(1,064)	(1,090)	(1,116)	(1,134)	(1,152)	(1,171)	(1,190)	(1,208)
Total stockholders' equity	152	123	93	69	48	27	170	155	142	127	112	96
Total liabilities and equity	308	314	346	315	293	276	301	289	277	264	249	242
Common shares outstanding (cover page) millions of shares	50	51	52	52	53	54	18	18	18	18	19	19

† Share count changed about 1/3 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (OM's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(46)	(39)*	(40)	(34)	(28)	(26)*	(26)	(19)	(18)	(19)*	(19)	(18)
Stock-based compensation	11*	9*	8	10*	6*	5*	3	3*	5*	4*	3	3*
Depreciation and amortization	1*	1*	1	1*	1*	1*	1	1*	1*	1*	1	1*
Net cash from operating activities	(34)*	(24)*	(46)	(33)*	(21)*	(16)*	(26)	(5)*	(6)*	(10)*	(13)	(10)*
Purchases of property and equipment	1*	1*	0	0*	0*	0*	0	0*	0*	0*	0	0*
Net cash from investing activities	30*	23*	(59)	39*	16*	108*	(78)	(31)*	3*	9*	8	14*
Proceeds from issuing common stock	—	year only	—	—	—	—	—	—	—	—	—	—
Proceeds from long-term debt	0*	33*	67	0*	0*	0*	98	0*	0*	0*	0	0*
Net cash from financing activities	4*	33*	69	0*	0*	(1)*	56	(0)*	0*	0*	1	(0)*
Net change in cash	(0)*	32*	(36)	6*	(5)*	91*	(48)	(36)*	(3)*	(1)*	(4)	4*

† Share count changed about 1/3 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Outset Medical	35	32	(9.6)*	18.8M	15.3 quarters	Q2 FY26 10-QJun 30, 2026
ClearPoint Neuro	46	12	(20)	32.1M	6.6 quarters	Q3 FY26 10-QSep 30, 2026
EBR Systems	59	2.6	(17)*	75.3M	5.0 quarters	Q2 FY26 10-QJun 30, 2026
Orthopediatrics	17	73	4.5*	26.1M	—	Q3 FY26 10-QSep 30, 2026
NeuroPace	13	23	(3.9)*	34.3M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Butterfly Network	122	33	(2.3)*	not reported	10.3 quarters	Q3 FY26 10-QSep 30, 2026
Pulse Biosciences	102	0.4	(19)*	71.3M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
SS Innovations International	14	not reported	(4.2)*	200.4M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Ceribell	42	29	(13)*	38.8M	7.8 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.